Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Veterinary Best Practices for Serial Sampling in Rodent PK Studies under EMA Guidelines

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Veterinary Best Practices for Serial Sampling in Rodent PK Studies under EMA Guidelines

CELL & GENE | RNA | BIOLOGICS

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Executive Summary

Executing pharmacokinetic (PK) studies for advanced biologics under European regulatory agency (EMA) guidelines requires stringent adherence to animal welfare standards, particularly concerning blood collection volumes in rodents. This asset details the technical and regulatory rationale for adopting serial sampling and microsampling techniques over traditional composite study designs. We outline how these refined methods yield higher-quality, more statistically robust PK data, reduce animal usage in alignment with 3Rs principles, and support accelerated Investigational New Drug (IND) application timelines.

Frequently Asked Questions (FAQ)

    What are the maximum blood volume collection limits for rodents under EMA guidelines?

    A: The EMA, along with other regulatory bodies, generally recommends that the total blood volume collected from a rodent should not exceed 15% of the circulating blood volume (CBV) within a 28-day period, and a single collection should not exceed 10% of CBV. For a typical 25g mouse, this translates to a maximum single draw of approximately 150-200 µL.

    How does serial sampling impact the statistical power of a PK study compared to composite sampling?

    A: Serial sampling, where multiple time points are collected from the same animal, significantly enhances statistical power. It reduces inter-animal variability, as each animal serves as its own control. This results in a more precise characterization of the PK profile with fewer animals compared to a composite design, where each time point is from a different animal group.

    What are the primary validation requirements for microsampling assays used in GxP studies?

    A: Bioanalytical assays for microsamples under GxP must be fully validated for parameters including precision, accuracy, selectivity, stability, matrix effects, and hematocrit effects. The validation must demonstrate that the small sample volume provides a reliable and reproducible measurement of the analyte concentration equivalent to larger volume samples.

    How do you mitigate the risk of hemolysis in serially collected rodent samples?

    A: Hemolysis is mitigated through proper technique and equipment. This includes using appropriate gauge needles or lancets for the collection site (e.g., saphenous vein), avoiding excessive pressure during collection, and ensuring immediate and correct sample processing with appropriate anticoagulants. The training and proficiency of technical staff directly impact data quality.

Optimizing PK Data Integrity Under EMA Volume Constraints

Generating a robust pharmacokinetic profile is fundamental to any preclinical program. For rodent studies governed by EMA regulations, the challenge is intensified by strict limits on blood collection volumes. The preferred scientific and ethical approach is serial sampling, which allows for the construction of a full PK curve from a single animal. This methodology directly contrasts with composite designs that require large cohorts and introduce significant biological variability.

By leveraging microsampling techniques, we can collect the necessary time points (typically 10-50 µL per sample) from an individual animal without exceeding physiological or regulatory limits. This refinement provides a clearer, more accurate PK profile by eliminating the statistical noise inherent in composite studies.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

Animal Welfare and the 3Rs

Our in vivo operations adhere to the highest standards of animal welfare, aligning with the guiding principles established by AAALAC International and the USDA. The adoption of serial microsampling is a direct implementation of the 3Rs principles:

  • Reduction: Fewer animals are required to achieve the same or higher statistical power.

  • Refinement: Minimally invasive techniques reduce animal stress and improve physiological normalcy, leading to more reliable data.

  • Replacement: While not a direct replacement, the data quality from refined rodent studies can reduce the need for duplicative or exploratory studies in higher species.

Parameter Traditional Composite Sampling Serial Microsampling
Animal Usage High (e.g., 3 animals per time point) Low (1 animal per profile)
Data Variability High (Inter-animal) Low (Intra-animal)
Blood Volume High (Terminal bleeds) Low (µL volumes)
Regulatory Alignment Acceptable, but less favored Strongly aligned with EMA/3Rs

The Preclinical Infrastructure for Advanced Therapeutics

Executing these sophisticated in vivo studies requires a specialized infrastructure designed for next-generation biologics. The logistical and technical demands of programs involving AAV vectors or cell-based constructs necessitate advanced operational capabilities.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

Aligning Study Design with Translational Goals

A well-designed preclinical optimization strategy is a prerequisite for programs navigating the path to regulatory approval. As highlighted in discussions on best practices for gene therapy programs, rigorous and well-planned preclinical studies support a successful regulatory submission [PMID: 25654329]. A poorly characterized PK profile can create significant delays.

The emphasis on refined, standardized procedures is echoed in work developing translatable methods for AAV vector administration. The development of standardized, guidance-based delivery techniques demonstrates the value of procedural consistency in generating data suitable for GxP studies and clinical translation [PMID: 30032644]. This same principle applies directly to sample collection: a standardized, refined sampling strategy ensures the resulting PK data is equally robust and reliable for regulatory review.

At our >100,000 sq ft GxP-compliant facility, we integrate these principles to support an 18-24 month IND timeline. Since the launch of the Franklin Biolabs brand in 2024, programs leveraging our preclinical services have maintained a 100% IND success rate, a testament to a methodology grounded in regulatory foresight and scientific precision.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities